title: [EMERGENCY TREATMENT OF BLEEDING IN PATIENTS TAKING WARFARIN].
abstract: Anticoagulant therapy with vitamin K antagonists (AVK) is an effective treatment and prevention of thrombosis. One of the major disadvantages of the AVK is a risk for serious bleeding. Prothrombin complex concentrates (PCC), fresh frozen plasma (FFP) and vitamin K1 are available for control of these situations. The experience of special team ofthe Scientific Center for Hematology was the basis for presented retrospective study. Three regimens of warfarin-related bleeding were compared: PCC+ VK for several bleeding, FFP+ VK for different clinical situations and VKfor light bleeding. PCC showed himself as effective and safe hemostatic agent. Transfusions of FFP were sometimes not effective, sometimes led to TACO. Supplementation of vitamin K1 for patients of I and II groups provided more stable control of hemostasis. In III group VK vas effective to stop bleeding. Two impotent sings for conclusion: necessary of laboratory monitoring, TEG first of all; individual balance of hemostasis base of bleeding or thrombotic risks.
authors.forename: N V
authors.initials: NV
authors.lastname: Prasolov
authors.forename: E M
authors.initials: EM
authors.lastname: Shulutko
authors.forename: A Yu
authors.initials: AY
authors.lastname: Bulanov
authors.forename: K V
authors.initials: KV
authors.lastname: Yatskov
authors.forename: O V
authors.initials: OV
authors.lastname: Shcherbakov
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D006490:Hemostatics / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D010951:Plasma Exchange; D012189:Retrospective Studies; D016896:Treatment Outcome; D010837:Vitamin K 1 / Q000008:administration & dosage / Q000627:therapeutic use; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; D006490:Hemostatics; C025667:prothrombin complex concentrates; D014859:Warfarin; D010837:Vitamin K 1